Evidence map›Paper›PMID 40279259›Full record

ArticleCurrent protocols2025

Cryptococcus neoformans Biofilm Formation and Quantification.

Oscar Romero, Davier Gutierrez-Gongora, Jennifer Geddes-McAlister

Abstract read
In one paragraph

Article in Current protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Antibiofilm activity of terbinafine, itraconazole and their combination against Sporothrix brasiliensis yeast-like form's biofilms.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Oscar RomeroDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.
Davier Gutierrez-GongoraDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.
Jennifer Geddes-McAlisterDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.ORCID https://orcid.org/0000-0002-4257-2096

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cryptococcus neoformans is an opportunistic fungal pathogen that heads the Fungal Priority Pathogen List published by the World Health Organization (WHO) in 2022. This pathogen is a primary cause of death for immunocompromised individuals (e.g., those with HIV/AIDS, the elderly, immunotherapy recipients), causing approximately 118,000 deaths yearly worldwide. C. neoformans relies on virulence factors that include a polysaccharide capsule, melanin, extracellular enzymes, and thermotolerance to initiate and sustain host infection. Additionally, similar to other fungal pathogens (e.g., Candida albicans), C. neoformans may develop a biofilm organization linked to more persistent cryptococcal infections. Cryptococcal biofilms are highlighted in cases of cryptococcal meningitis, in which biofilm-like structures form that are highly resistant to host immune response and to antifungal therapies. In this regard, fungal biofilm formation has become an important area of study as a means to improve our understanding of the mechanisms regulating biofilm formation and infection and to advance the discovery of antibiofilm therapeutics. To assess biofilm properties and compare across treatments, quantification and evaluation of cell viability are important. Herein, we describe a standardized method to establish a cryptococcal biofilm and quantify total biomass and cell viability. © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Culturing and biofilm formation Basic Protocol 2: Biofilm quantification Alternate Protocol: Biofilm viability assay.

Indexed as

BiofilmsCryptococcus neoformansHumansbiofilm, Cryptococcus neoformanscrystal violetfungal pathogenquantificationXTT

Identifiers

PMID40279259
PMCPMC12026377

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.